FibroGen (NASDAQ: FGEN) reported Q1 EPS of ($0.33), $0.08 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $55.9 million versus the consensus estimate of $36.45 million.

GUIDANCE:

FibroGen sees FY2024 revenue of $120-135 million, versus the consensus of $155.3 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.